Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.98
CELG's Cash to Debt is ranked lower than
80% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CELG: 0.98 )
Ranked among companies with meaningful Cash to Debt only.
CELG' s 10-Year Cash to Debt Range
Min: 0.03  Med: 1.88 Max: No Debt
Current: 0.98
Equity to Asset 0.36
CELG's Equity to Asset is ranked lower than
80% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CELG: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
CELG' s 10-Year Equity to Asset Range
Min: -0.68  Med: 0.60 Max: 0.92
Current: 0.36
-0.68
0.92
Interest Coverage 14.30
CELG's Interest Coverage is ranked lower than
89% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 14.30 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s 10-Year Interest Coverage Range
Min: 4.47  Med: 23.69 Max: 428.04
Current: 14.3
4.47
428.04
F-Score: 7
Z-Score: 7.21
M-Score: -2.57
WACC vs ROIC
16.86%
38.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.72
CELG's Operating margin (%) is ranked higher than
92% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CELG: 31.72 )
Ranked among companies with meaningful Operating margin (%) only.
CELG' s 10-Year Operating margin (%) Range
Min: -2309.09  Med: 5.17 Max: 32.84
Current: 31.72
-2309.09
32.84
Net-margin (%) 26.08
CELG's Net-margin (%) is ranked higher than
90% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CELG: 26.08 )
Ranked among companies with meaningful Net-margin (%) only.
CELG' s 10-Year Net-margin (%) Range
Min: -2309.09  Med: 8.57 Max: 28.88
Current: 26.08
-2309.09
28.88
ROE (%) 36.34
CELG's ROE (%) is ranked higher than
96% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CELG: 36.34 )
Ranked among companies with meaningful ROE (%) only.
CELG' s 10-Year ROE (%) Range
Min: -425.42  Med: 8.93 Max: 33.02
Current: 36.34
-425.42
33.02
ROA (%) 12.99
CELG's ROA (%) is ranked higher than
91% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CELG: 12.99 )
Ranked among companies with meaningful ROA (%) only.
CELG' s 10-Year ROA (%) Range
Min: -166.78  Med: 4.51 Max: 15.8
Current: 12.99
-166.78
15.8
ROC (Joel Greenblatt) (%) 208.68
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CELG: 208.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.72  Med: 99.64 Max: 212.3
Current: 208.68
-1378.72
212.3
Revenue Growth (3Y)(%) 20.60
CELG's Revenue Growth (3Y)(%) is ranked higher than
78% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CELG: 20.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CELG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 35.70 Max: 166.8
Current: 20.6
0
166.8
EBITDA Growth (3Y)(%) 20.40
CELG's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CELG: 20.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CELG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 21.90 Max: 75.6
Current: 20.4
0
75.6
EPS Growth (3Y)(%) 19.00
CELG's EPS Growth (3Y)(%) is ranked higher than
76% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CELG: 19.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CELG' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.2  Med: 23.55 Max: 118.1
Current: 19
-63.2
118.1
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CELG Guru Trades in Q3 2014

John Hussman 25,000 sh (New)
Louis Moore Bacon 55,000 sh (New)
Stanley Druckenmiller 560,600 sh (+103.12%)
Ken Fisher 232,137 sh (+77.12%)
RS Investment Management 86,904 sh (+15.71%)
Mario Gabelli 25,760 sh (+11.42%)
Ronald Muhlenkamp 146,940 sh (+1.94%)
Pioneer Investments 3,080,374 sh (unchged)
Steven Cohen Sold Out
George Soros Sold Out
Joel Greenblatt Sold Out
Jeremy Grantham Sold Out
Jim Simons 30,400 sh (-93.87%)
» More
Q4 2014

CELG Guru Trades in Q4 2014

Joel Greenblatt 10,259 sh (New)
Steven Cohen 110,400 sh (New)
Paul Tudor Jones 3,776 sh (New)
Pioneer Investments 3,376,570 sh (+9.62%)
Jim Simons Sold Out
John Hussman Sold Out
Louis Moore Bacon Sold Out
Ken Fisher 227,331 sh (-2.07%)
Mario Gabelli 24,960 sh (-3.11%)
RS Investment Management 76,482 sh (-11.99%)
Stanley Druckenmiller 434,100 sh (-22.57%)
Ronald Muhlenkamp 86,240 sh (-41.31%)
» More
Q1 2015

CELG Guru Trades in Q1 2015

Lee Ainslie 2,230 sh (New)
Bill Frels 1,776 sh (New)
Ray Dalio 24,296 sh (New)
Murray Stahl 5,000 sh (New)
Jim Simons 425,600 sh (New)
Joel Greenblatt 17,987 sh (+75.33%)
RS Investment Management 97,369 sh (+27.31%)
Pioneer Investments 3,475,247 sh (+2.92%)
Ken Fisher 229,918 sh (+1.14%)
Steven Cohen 1,000,200 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 24,940 sh (-0.08%)
Ronald Muhlenkamp 85,540 sh (-0.81%)
Paul Tudor Jones 3,180 sh (-15.78%)
Stanley Druckenmiller 195,975 sh (-54.85%)
» More
Q2 2015

CELG Guru Trades in Q2 2015

Louis Moore Bacon 50,000 sh (New)
Ken Heebner 110,000 sh (New)
Paul Tudor Jones 21,062 sh (+562.33%)
Jim Simons 1,006,838 sh (+136.57%)
RS Investment Management 106,224 sh (+9.09%)
RS Investment Management 106,224 sh (+9.09%)
Pioneer Investments 3,523,050 sh (+1.38%)
Murray Stahl 5,000 sh (unchged)
Bill Frels 1,776 sh (unchged)
Lee Ainslie 2,230 sh (unchged)
Ronald Muhlenkamp Sold Out
Ray Dalio Sold Out
Stanley Druckenmiller Sold Out
Ken Fisher 224,399 sh (-2.40%)
Mario Gabelli 24,265 sh (-2.71%)
Joel Greenblatt 7,778 sh (-56.76%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 47.10
CELG's P/E(ttm) is ranked lower than
60% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. CELG: 47.10 )
Ranked among companies with meaningful P/E(ttm) only.
CELG' s 10-Year P/E(ttm) Range
Min: 17.91  Med: 48.95 Max: 618.59
Current: 47.1
17.91
618.59
Forward P/E 20.45
CELG's Forward P/E is ranked higher than
59% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. CELG: 20.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 47.00
CELG's PE(NRI) is ranked lower than
62% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. CELG: 47.00 )
Ranked among companies with meaningful PE(NRI) only.
CELG' s 10-Year PE(NRI) Range
Min: 17.81  Med: 48.77 Max: 482.5
Current: 47
17.81
482.5
P/B 15.52
CELG's P/B is ranked lower than
89% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CELG: 15.52 )
Ranked among companies with meaningful P/B only.
CELG' s 10-Year P/B Range
Min: 4.02  Med: 9.32 Max: 23.64
Current: 15.52
4.02
23.64
P/S 12.24
CELG's P/S is ranked lower than
53% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. CELG: 12.24 )
Ranked among companies with meaningful P/S only.
CELG' s 10-Year P/S Range
Min: 5.37  Med: 10.88 Max: 28.35
Current: 12.24
5.37
28.35
PFCF 38.76
CELG's PFCF is ranked higher than
52% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. CELG: 38.76 )
Ranked among companies with meaningful PFCF only.
CELG' s 10-Year PFCF Range
Min: 14.96  Med: 36.75 Max: 2925.5
Current: 38.76
14.96
2925.5
POCF 35.95
CELG's POCF is ranked lower than
54% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. CELG: 35.95 )
Ranked among companies with meaningful POCF only.
CELG' s 10-Year POCF Range
Min: 13.82  Med: 33.92 Max: 937.83
Current: 35.95
13.82
937.83
EV-to-EBIT 35.19
CELG's EV-to-EBIT is ranked lower than
55% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. CELG: 35.19 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s 10-Year EV-to-EBIT Range
Min: -26.2  Med: 36.50 Max: 191.9
Current: 35.19
-26.2
191.9
PEG 2.03
CELG's PEG is ranked higher than
55% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. CELG: 2.03 )
Ranked among companies with meaningful PEG only.
CELG' s 10-Year PEG Range
Min: 1.38  Med: 2.05 Max: 2.92
Current: 2.03
1.38
2.92
Shiller P/E 72.73
CELG's Shiller P/E is ranked lower than
68% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 44.71 vs. CELG: 72.73 )
Ranked among companies with meaningful Shiller P/E only.
CELG' s 10-Year Shiller P/E Range
Min: 56.57  Med: 128.11 Max: 2211
Current: 72.73
56.57
2211
Current Ratio 3.34
CELG's Current Ratio is ranked lower than
57% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CELG: 3.34 )
Ranked among companies with meaningful Current Ratio only.
CELG' s 10-Year Current Ratio Range
Min: 1.35  Med: 6.66 Max: 44.53
Current: 3.34
1.35
44.53
Quick Ratio 3.20
CELG's Quick Ratio is ranked lower than
56% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CELG: 3.20 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s 10-Year Quick Ratio Range
Min: 1.13  Med: 6.56 Max: 44.15
Current: 3.2
1.13
44.15
Days Inventory 346.57
CELG's Days Inventory is ranked lower than
89% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. CELG: 346.57 )
Ranked among companies with meaningful Days Inventory only.
CELG' s 10-Year Days Inventory Range
Min: 49.98  Med: 122.84 Max: 584
Current: 346.57
49.98
584
Days Sales Outstanding 55.16
CELG's Days Sales Outstanding is ranked higher than
57% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CELG: 55.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s 10-Year Days Sales Outstanding Range
Min: 42.33  Med: 57.52 Max: 464.55
Current: 55.16
42.33
464.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 516.83
CELG's Price/Tangible Book is ranked lower than
100% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. CELG: 516.83 )
Ranked among companies with meaningful Price/Tangible Book only.
CELG' s 10-Year Price/Tangible Book Range
Min: 3.97  Med: 12.10 Max: 482.23
Current: 516.83
3.97
482.23
Price/Projected FCF 3.19
CELG's Price/Projected FCF is ranked higher than
61% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CELG: 3.19 )
Ranked among companies with meaningful Price/Projected FCF only.
CELG' s 10-Year Price/Projected FCF Range
Min: 1.66  Med: 6.47 Max: 122.67
Current: 3.19
1.66
122.67
Price/Median PS Value 1.13
CELG's Price/Median PS Value is ranked lower than
54% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. CELG: 1.13 )
Ranked among companies with meaningful Price/Median PS Value only.
CELG' s 10-Year Price/Median PS Value Range
Min: 0.51  Med: 1.25 Max: 7.51
Current: 1.13
0.51
7.51
Price/Peter Lynch Fair Value 2.14
CELG's Price/Peter Lynch Fair Value is ranked lower than
56% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. CELG: 2.14 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CELG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.36  Med: 1.33 Max: 5.1
Current: 2.14
0.36
5.1
Price/Graham Number 31.72
CELG's Price/Graham Number is ranked lower than
98% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. CELG: 31.72 )
Ranked among companies with meaningful Price/Graham Number only.
CELG' s 10-Year Price/Graham Number Range
Min: 2.89  Med: 7.75 Max: 29.6
Current: 31.72
2.89
29.6
Earnings Yield (Greenblatt) (%) 2.80
CELG's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CELG: 2.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CELG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 2.60 Max: 6.6
Current: 2.8
0.5
6.6
Forward Rate of Return (Yacktman) (%) 23.70
CELG's Forward Rate of Return (Yacktman) (%) is ranked higher than
71% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 13.70 vs. CELG: 23.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CELG' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -0.1  Med: 1.10 Max: 34.8
Current: 23.7
-0.1
34.8

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 9,228 11,218 13,759
EPS($) 4.65 6.06 7.90
EPS without NRI($) 4.65 6.06 7.90

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CELG.Mexico, CG3.Germany, CELG.Switzerland, 0QYA.UK,
Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of Thalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for CELG

Headlines

Articles On GuruFocus.com
Positions Aug 23 2015 
Positions Aug 23 2015 
Stocks Jul 30 2015 
scottrade Jul 24 2015 
scottrade Jul 24 2015 
scottrade Jul 24 2015 
scottrade Jul 24 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 

More From Other Websites
Facebook, IBD 50's 5 Most Liquid Stocks Setting Up Aug 30 2015
4 IBD 50 Drugmakers Getting Lift From New Treatments Aug 29 2015
Cramer: Big lessons from this week's flash crash Aug 28 2015
Gilead & Amgen Account for Nearly 75% of the Biotech Profit Pool Aug 28 2015
Cramer: China & biotech - it's complicated Aug 27 2015
CELGENE CORP /DE/ Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Aug 27 2015
Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases Aug 27 2015
Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases Aug 27 2015
Best way to play the market Aug 27 2015
'We See Opportunity in Biogen, Gilead and Regeneron,' Morgan Stanley Says Aug 27 2015
Celgene Corporation to Webcast Upcoming Investor Conferences in September Aug 26 2015
Short Sellers Become More Focused in Major Biotechs Aug 26 2015
Celgene Corporation to Webcast Upcoming Investor Conferences in September Aug 26 2015
Celgene Corporation to Webcast Upcoming Investor Conferences in September Aug 26 2015
Cramer: Hard selloff lessons learned Aug 25 2015
Celgene draws vote of confidence Aug 25 2015
AMAG is a Hidden Biotech Gem That is Exploding Aug 25 2015
Celgene Announces Expiration of Cash Tender Offer for Shares of Receptos, Inc. Aug 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK